Loading
A phase 3 trial of Durvalumab, Tremelimumab, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). is a phase 3 interventional study registered as NCT03164616 by AstraZeneca, with 1186 participants enrolled, started 2017-06-01 and due to reach its primary completion in 2021-03-12. Interventions recorded: Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin. Conditions listed: Non Small Cell Lung Cancer NSCLC. Results were posted on ClinicalTrials.gov in 2022; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,186 enrolled.
95% CI 4.7 to 6.5; Figures from the ClinicalTrials.gov results section (first posted 2022-04-07), not from a publication · 95% CI 4.6 to 5.8
Source95% CI 11.4 to 14.7; Figures from the ClinicalTrials.gov results section (first posted 2022-04-07), not from a publication · 95% CI 10.5 to 13.1
SourceFigures from the ClinicalTrials.gov results section (first posted 2022-04-07), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS); D + SoC Compared With SoC Aloneprimary | D + SoC | 338 | 5.5 months | 0.74 (0.62 to 0.885) | 0.00093 | link |
| SoC Alone | 337 | 4.8 months | ||||
| Overall Survival (OS); D + SoC Compared With SoC Aloneprimary | D + SoC | 338 | 13.3 months | 0.86 (0.724 to 1.016) | 0.07581 | link |
| SoC Alone | 337 | 11.7 months | ||||
| Objective Response Rate (ORR) | T + D + SoC | 335 | 46.3% | - | - | link |
| D + SoC | 330 | 48.5% | ||||
| SoC Alone | 332 | 33.4% |
Shares Tremelimumab, Durvalumab, Gemcitabine, AstraZeneca.
Shares Tremelimumab, Durvalumab, Gemcitabine, AstraZeneca.
Shares Tremelimumab, Durvalumab, AstraZeneca, Cisplatin.
Shares Durvalumab, Paclitaxel / nab-paclitaxel, Gemcitabine, AstraZeneca.
Shares Durvalumab, Paclitaxel / nab-paclitaxel, Gemcitabine, AstraZeneca.
Shares Tremelimumab, Durvalumab, Paclitaxel / nab-paclitaxel, AstraZeneca.
Shares Durvalumab, AstraZeneca, Cisplatin, Carboplatin.
Shares Tremelimumab, Durvalumab, AstraZeneca, Immune checkpoint inhibitors.